Cibc World Markets Corp Makes New Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Cibc World Markets Corp purchased a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 27,460 shares of the biopharmaceutical company’s stock, valued at approximately $259,000.

A number of other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP boosted its holdings in Amicus Therapeutics by 13.5% during the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after purchasing an additional 2,856,101 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Amicus Therapeutics during the 3rd quarter worth about $13,530,000. Rice Hall James & Associates LLC boosted its stake in shares of Amicus Therapeutics by 41.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company’s stock worth $12,916,000 after buying an additional 398,942 shares during the last quarter. Old West Investment Management LLC grew its holdings in shares of Amicus Therapeutics by 617.2% in the 3rd quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock valued at $3,636,000 after acquiring an additional 292,976 shares in the last quarter. Finally, PDT Partners LLC bought a new position in shares of Amicus Therapeutics in the 3rd quarter valued at about $2,702,000.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $8.62 on Wednesday. Amicus Therapeutics, Inc. has a 52-week low of $8.52 and a 52-week high of $12.65. The stock has a market cap of $2.65 billion, a PE ratio of -47.89, a P/E/G ratio of 1.51 and a beta of 0.69. The firm has a 50-day moving average of $9.33 and a 200-day moving average of $10.01. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39.

Wall Street Analyst Weigh In

Several research analysts have weighed in on FOLD shares. Wells Fargo & Company lowered their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Morgan Stanley restated an “equal weight” rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.